![]() |
|
|
Vol. 303, Issue 2, 592-600, November 2002
Prassis Sigma-Tau Research Institute, Settimo Milanese, Italy (R.M., A.S., S.D.M, P.M., P.F.); Sigma-Tau R & D, Pomezia, Italy (G.G.M., M.F.L., P.C.); Department of Biotechnologies and Biosciences, Università degli Studi di Milano, Bicocca, Italy (M.R., A.Z.); Centre National de la Recherche Scientifique, Montpellier, France (J.P.G.); and Università Vita e Salute, Milan, Italy (G.B.)
| |
Abstract |
|---|
|
|
|---|
The novel Na+/K+-ATPase inhibitor (E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744) was characterized for its inotropic and toxic properties. Inhibition potency on dog kidney Na+/K+-ATPase was comparable (0.43 µM) to that of digoxin (0.45 µM). PST2744 concentration-dependently increased force of contraction in guinea pig atria and twitch amplitude in isolated guinea pig myocytes; in the latter, aftercontractions developed significantly less than with digoxin. Intravenous infusion of 0.2 mg/kg/min PST2744 in anesthetized guinea pigs exerted an immediate and long-lasting inotropic effect (ED80 of 1.89 ± 0.37 mg/kg) without causing lethal arrhythmias up to a cumulative dose of 18 mg/kg. Conversely, an equieffective infusion of digoxin (0.016 mg/kg/min; ED80 of 0.32 mg/kg) caused lethal arrhythmias at a cumulative dose of 0.81 mg/kg. At a higher rate (0.4 mg/kg/min), PST2744 induced lethal arrhythmias, with a lethal dose/ED80 ratio significantly greater than digoxin (20.2 ± 6.3 versus 3.23 ± 0.55, p < 0.05). Decay of the inotropic effect (t1/2, min) was significantly faster for PST2744 (6.0 ± 0.39) than for digoxin (18.3 ± 4.5, p < 0.05). In anesthetized dogs, PST2744 dose-dependently increased maximum velocity of pressure rise (+dP/dtmax) in the range 32 to 500 µg/kg i.v. and was safer than digoxin. In conscious dogs with a healed myocardial infarction, PST2744 significantly increased resting values of +dP/dtmax, left ventricular pressure, and SPB, and increased +dP/dtmax throughout treadmill exercise while reverting the increase in left ventricular end diastolic pressure seen in control animals. Digoxin significantly decreased basal heart rate, while not affecting the hemodynamic response to exercise. Thus, PST2744 represents a new class of Na+/K+-ATPase inhibitors endowed with inotropic activity comparable with that of digitalis but having greater safety.
| |
Introduction |
|---|
|
|
|---|
Improvement
of heart failure (HF) treatment remains a major medical challenge for
the coming years. Despite achievement of considerable progress during
the last two decades, none of the available therapeutic agents is fully
satisfactory, and HF remains a disease with a poor prognosis (Kannel,
2000
). The goal of ameliorating quality of life, exercise capability,
and survival is only partially met by angiotensin-converting
enzyme inhibitors, diuretics, vasodilators, glycosides, and
-blocking agents, regardless of their being used in combined therapy
(Consensus Recommendations for the Management of Chronic Heart Failure,
1999
). Therefore, the need still remains for novel drugs able to
increase workload tolerance and to reduce morbidity and mortality.
Worsening of survival found with chronic administration of
inotropic agents that increase intracellular cAMP (phosphodiesterase
inhibitors and sympathomimetic amines) (The Xamoterol in Severe Heart
Failure Study Group, 1990
; Packer et al., 1991
; Cohn et al., 1998
) and
the well known arrhythmogenic effects of cardiac glycosides have led to
the general view that drug-induced inotropy per se may be associated
with an increased risk of death. On the other hand, such a view is
challenged by the outcome of the Digitalis Investigation Group trial
(The Digitalis Investigation Group, 1997
), a study specifically
designed to assess the effect of long-term digoxin treatment on
survival. Although improving the functional status and reducing the
rate of hospitalization due to HF recurrences, digoxin did not affect
overall mortality in patients receiving diuretics and
angiotensin-converting enzyme inhibitors. This can be interpreted as if
a beneficial increase in inotropy were balanced by a concomitant
increase in the incidence of lethal arrhythmias, both effects being
associated to digoxin administration. Thus, the proarrhythmic effects
of inotropic agents, rather than inotropy per se, may be responsible
for an increase in mortality in HF patients. This provides a strong
motivation for the search of inotropic agents devoid of proarrhythmic
effects. Inhibition of
Na+/K+-ATPase, the
"classical" mechanism of glycoside inotropy, is generally regarded
with suspicion because of the view that the resulting increase in
intracellular Ca2+ may be the basis for both
inotropic and proarrhythmic effects. However, evidence that
Na+/K+-ATPase inhibition
may not be the only site of digitalis action (Sagawa et al., 2002
),
opens the possibility of a dissociation between inotropic and
proarrhythmic effects of
Na+/K+-ATPase inhibitors.
The present study investigates the pharmacological properties of
(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride (PST2744) (Fig. 1), a
derivative of 3,6,17-androstanetrione chemically unrelated to cardiac
glycosides but able to inhibit Na+/K+-ATPase and increase
cardiac inotropy with similar potency. PST2744 stems from a molecular
modeling study proposing a new three-dimensional model for the binding
of cassaine at the digitalis receptor site (De Munari et al., 1998
).
Suitability of the model was corroborated by the activity of novel
potent inhibitors of the
Na+/K+-ATPase devoid of any
of the structural characteristics peculiar to the digitalis structure
(Gobbini et al., 2001
). The evaluation presented herein, extending from
in vitro to whole animal studies, provides concordant evidence of a
substantial difference between PST2744 and digoxin, mainly consisting
of a sharp dissociation between toxic and inotropic effects.
|
| |
Materials and Methods |
|---|
|
|
|---|
Studies were carried out in accordance with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
In Vitro Assays
Inhibition of Na+/K+-ATPase.
Dog or
guinea pig kidney outer medulla was homogenized with a Polytron in 250 mM sucrose and 30 mM histidine, at pH 7.2. The homogenate was
centrifuged at 6,000g for 15 min at 4°C and the supernatant at 48,000g for 30 min at 20°C with SDS and
then layered onto a discontinuous sucrose density gradient (10, 15, and
29%) and centrifuged at 60,000 rpm for 115 min at 4°C. The pellet
was resuspended in 25 mM imidazole and 1 mM EDTA, pH 7.5. Protein content was measured by the method of Lowry et al. (1951)
.
Na+/K+-ATPase activity was
measured after the release of 32P from
[32P]ATP. Increasing concentrations of
compounds were preincubated with purified enzyme for 10 min at 37°C
in 120 µl of final volume of medium containing 140 mM NaCl, 3 mM
MgCl2, 50 mM HEPES-Tris, and 3 mM ATP, pH 7.5. After preincubation, 10 µl of incubation solution containing 10 mM
KCl and 20 nCi of [32P]ATP (0.5-3 Ci/mmol) was
added, and the reaction was carried out for 15 min at 37°C before
being stopped by acidification with 30% (v/v) perchloric acid.
32P was separated by centrifugation with
activated charcoal and radioactivity measured by liquid scintillation
counting. Inhibitory activity was expressed as percentage of control
sample, carried out in the absence of standard compound.
IC50 was calculated by weighed nonlinear
regression curve fitting to the mass-action equilibrium.
Evaluation of Receptor Specificity. Radioligand binding to a number of receptors was carried out by MDS Panlabs Pharmacology Services (Taipei, Taiwan) on crude membrane preparations according to published procedures, and by using appropriate reference standards. Interaction with human phosphodiesterases III was evaluated by an enzymatic assay. Interaction with Na+ channels was investigated in paced rat left atria.
Ex Vivo Assays
Inotropy in Isolated Guinea Pig Ventricular Myocytes.
Guinea
pigs (Charles River Italia, Calco, Italy) weighing 200 to 300 g
were anesthetized with a xylazine (1.8 mM) and ketamine (22 mM) mix,
killed through cervical dislocation, and exsanguinated. Ventricular
myocytes were enzymatically dissociated with a procedure described
previously (Zaza et al., 1998
) and used within 12 h from
isolation. The myocyte suspension was placed in a 30-mm Petri dish on
the stage of an inverted microscope (Nikon, Tokyo, Japan). The dish was
perfused at 2 ml/min with standard external Tyrode's solution,
containing 154 mM NaCl, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 5 mM HEPES-NaOH, and 5.5 mM
D-glucose, adjusted to pH 7.35. The cell under study was
held at the mouth of a thermostated manifold pipette, which allowed
exposing the cell to different solutions, with changes completed in
about 1 s. The solution temperature was monitored at the pipette
tip with a fast-response digital thermometer (Physitemp Instruments,
Clifton, NJ) and kept at 35 ± 0.5°C. Cells were electrically
stimulated at 2 Hz through a micropipette electrode positioned in the
vicinity of the cell. Extracellular stimulation was selected to avoid
cytoplasm contamination and buffering, which might interfere with cell
contractility and its modulation. Cell motion was monitored at a
sampling rate of 200 Hz by a video edge detector (Crescent Electronics,
Sandy, UT) connected to a noninterfaced camera. A voltage signal
proportional to cell length was generated by the device, digitized at 1 KHz (Digidata 1200; Axon Instruments, Union City, CA), and recorded on
a PC through dedicated software (pClamp 7.0; Axon Instruments). Twitch
amplitude was measured as the difference between peaks and troughs of
the voltage signal.
Inotropy in Isolated Guinea Pig Atria. Male guinea pigs (350-450 g) were decapitated, the heart was rapidly excised, and the left atrium was set up under 500 mg of tension in 5-ml baths containing a solution of the following composition: 132 mM NaCl, 5.6 mM KCl, 1.8 mM CaCl2, 25 mM NaH2PO4, 11 mM glucose, and 13 mM saccarose, oxygenated with 95% O2/5% CO2, and maintained at 32°C. The preparations were stimulated to contract by means of platinum electrodes at 1 Hz, with pulses of 1-ms duration and amplitude twice the threshold. After 60-min equilibration, the compounds under study were added to the bath in cumulative concentrations until a plateau was reached or arrhythmias occurred. Results were expressed as percentage of variation of basal force. EC50 were calculated graphically.
In Vivo Assays
Inotropic and Toxic Effect in Anesthetized Guinea Pigs. Male guinea pigs (350-450 g) were used. Experiments were performed on normal animals or pressure-overloaded animals and their respective sham-operated controls. Pressure overload was induced in ketamine-xilazine (100-5 mg/kg i.p.)-anesthetized animals by constriction of the descending thoracic aorta; experiments were carried out 8 weeks later.
Normal animals, sham-operated, or pressure-overloaded animals were anesthetized with urethane (1.5 g/kg i.p.). Body temperature was maintained at 37°C by a homeothermic blanket system (Harvard Apparatus, South Natick, MA). A microtip pressure transducer (SPR-407; Millar Instruments, Houston, TX) was introduced into the left ventricle through the right carotid artery to measure ventricular pressure (LVP); the transducer was coupled with a transducer amplifier (model 13-4615-50; Gould, Cleveland, OH). Recordings were fed to an RS 3800 polygraph (Gould) and to an AST 486 computer and analyzed by IDAS software (Biomedica Mangoni, Pisa, Italy). A polyethylene 50 cannula was inserted into a jugular vein for drug infusion and the trachea was intubated to facilitate spontaneous respiration. ECG was telemetrically recorded by means of a TA10CA-F40 transmitter and stored on a hard disk (Dataquest software; Data Sciences, St. Paul, MN). After a stabilization period, the test substance was injected at the rate of 0.16 ml/min by means of a P22 pump (Harvard Apparatus) until the animal died, or up to a maximum of 90 min. In a second set of experiments, infusion was stopped at fixed times (40 min for digoxin and 90 min for PST2744) to evaluate the rate of recovery of basal maximum velocity of pressure rise (+dP/dtmax). The following parameters were obtained for each animal: heart rate (HR), LVP, +dP/dtmax, and maximum velocity of pressure fall (
dP/dtmax). In addition, the times elapsed
until 80%, and maximum increase, of +dP/dtmax
over basal were determined to calculate the dose increasing basal
+dP/dtmax by 80% (ED80)
and dose inducing the maximum increase in
+dP/dtmax (EDmax). The dose
administered until the onset of arrhythmias and the lethal dose (dose
inducing death, LD) were also calculated. The latter are given as
mean ± S.E.M. when possible or as the maximum dose administered
during 90 min.
Dose-Response in Anesthetized Dogs. Beagle dogs (10-11 kg; Green Hill, Brescia, Italy) were used after being fasted for 18 h, under pentobarbital anesthesia (25 mg/kg bolus followed by 1 mg/kg/h infusion), with room air ventilation (positive pressure ventilator; Harvard Apparatus). Body temperature was maintained at 38°C by a thermostatic blanket. A 6F Millar double microtip transducer (Millar Instruments) connected to two AC preamplifiers (model 612; Biomedica Mangoni) was introduced into the left ventricle via a femoral artery for simultaneous measurement of aortic and left ventricle pressures. ECG (lead II) was recorded by subcutaneous needle electrodes (ECG recorder model 613; Biomedica Mangoni). After adequate stabilization of hemodynamic parameters, increasing doses of compounds under study were injected in a semicumulative manner by slow bolus administration. Effects were measured at their maximum or 15 min after compound administration.
Hemodynamic Effects in Dogs with Myocardial Infarction during Exercise. Surgical procedure. Animals under pentobarbital anesthesia (25 mg/kg i.v. bolus followed by 2 mg/kg/h infusion) were implanted with one solid-state pressure transducer (PA 4.5-X6; Könisberg Instruments, Pasadena, CA) into the left ventricle and one into the aortic arch to monitor left venticular and aortic pressures. A hydraulic occluder was placed around the left circumflex coronary artery, proximal to the marginal branch to induce acute ischemia. The leads were tunneled under the skin to exit at the nape of the neck. Myocardial infarction was induced by a ligature on the second segment of the left anterior descending coronary artery. Animals were placed in an intensive care setting, and received analgesic (tramadol i.m. every 12 h) and antibiotic (ceftazidime) therapy for 2 and 5 days, respectively.
Exercise protocol. The treadmill exercise program lasted 18 min, starting with a 3-min warm-up at 4 km/h. Thereafter, speed was increased to 9.5 km/h and then grade was increased to 4, 8, 12, and 16%. Each setting was maintained for 3 min. Animals were trained twice a week for 2 weeks before entering the study. ECG, LVP, and aortic pressures were monitored throughout the exercise test. Susceptibility to ventricular fibrillation was assessed during the last minute of exercise, when heart rate was approximately 220 bpm, by occluding the left circumflex artery. The treadmill was then abruptly stopped and the occlusion maintained for 2 min longer. The hemodynamic values reported were taken 15 min after compound administration, or at the maximum effect observed.
PST2744 (300 µg/kg) or digoxin (75 µg/kg) were given by i.v. bolus 10 and 20 min before starting the exercise, respectively, and compared with vehicle. The following variables, HR, ECG, LVP, and aortic pressures, were recorded through a computerized acquisition system (IOX 1.5; Emka Technologies, Paris, France), which calculated the left ventricular rates of pressure changes. Data were analyzed from the real-time digitized recordings. Control values were obtained before compound administration.Compounds
PST2744 was synthesized at Prassis Laboratories (U.S. patent 5914324). For in vitro studies, PST2744 was dissolved in water and digoxin in 4% DMSO. For studies in isolated myocytes, stock solutions of PST2744 (10 mM in distilled water) and digoxin (10 mM in DMSO) were diluted in Tyrode's solution. The maximum final concentration of DMSO was 0.05%.
For in vivo studies PST2744 was dissolved in physiological solution (guinea pigs) or in the vehicle of Lanoxin (Wellcome Italia, Pomezia, Italy). Digoxin (batch 75H0677; Sigma Italia, Milano, Italy) was dissolved in the vehicle of Lanoxin (quantity in 1 ml: 0.105 ml of ethanol, 0.415 g of propylene glycol, 0.75 mg of citric acid, 0.452 mg of sodium phosphate dibase, and distilled water qs to 1 ml). The vehicle was diluted with physiological solution to a final percentage of 35%. Urethane was purchased from Fluka (Buchs, Switzerland), ketamine (Inoketam) from Virbac (Carros, France), and xylazine (Rompun) from Bayer AG (Leverkusen, Germany).
Statistical Analysis
Data are presented as means ± S.E.M. Student's t tests for paired or unpaired observations and one-way analysis of variance were used for comparison of numeral variables. Dose dependence of effect was evaluated by linear regression analysis on individual data points. Differences among proportions were tested by chi square analysis (SAS 6.12 software). A p < 0.05 is used to define statistical significance.
| |
Results |
|---|
|
|
|---|
In Vitro Studies
Inhibition of Na+/K+-ATPase. PST2744 inhibited the Na+/K+-ATPase activity from dog kidney with an IC50 value of 0.43 ± 0.15 µM. Under the same conditions, digoxin IC50 was 0.45 ± 0.07 µM. Inhibition of Na+/K+-ATPase activity in preparations from guinea pig kidney yielded potencies of 8.5 µM for PST2744 and 1.3 µM for digoxin. Thus, although PST2744 activity was 20-fold lower in this species, digoxin potency differed by less than 3-fold.
Selectivity of Receptor Interaction.
The interaction of
PST2744 with several receptors was investigated at a concentration of
10 µM. The compound did not significantly interact with adenosine,
- and
-adrenergic, dopamine, estrogens, GABA, glucocorticoid,
glutamate, glycine, histamine, insulin, muscarinic, opiate,
progesterone, serotonin, and testosterone receptors. Similarly, no
interaction could be demonstrated with calcium, potassium, or sodium
channels, or with the phorbol ester or phosphodiesterases III.
Ex Vivo Studies
Inotropy and Toxicity in Isolated Guinea Pig Ventricular
Myocytes.
In this set of experiments, the effects of PST2744 and
digoxin on the stimulated twitch were compared in single myocytes
isolated from the guinea pig ventricle. Measurements were performed
during steady-state electrical stimulation at 2 Hz. Twitch amplitude was expressed as cell shortening normalized (percentage) to relaxed cell length. To minimize the impact of intercellular variability on the
shape of the dose-response curve, at least a low and a high
concentration were tested in each cell. A total of 105 cells from 11 animals was used, with a minimum of seven cells at each drug
concentration. Both PST2744 and digoxin caused a
concentration-dependent increase in twitch amplitude (Fig.
2a). At high concentrations, further
increments of inotropic effect were often associated with the
appearance of unstimulated twitches of irregular amplitude (aftercontractions; Fig. 2b), which prevented achievement of a plateau.
Whenever aftercontractions appeared during development of the response,
drug effect was expressed as the increment of twitch amplitude achieved
just before the first aftercontraction had developed. Threshold drug
concentrations were roughly similar for the two drugs, but the steep
portion of PST2744 response curve was shifted to the right (Fig. 2a).
The graphically estimated concentrations increasing twitch amplitude to
150% of basal were approximately 4 µM for PST2744 and 1 µM for
digoxin; nonetheless, the maximum inotropic effect that could be
achieved with the two agents was similar (88.9 ± 13.4 versus
99.6 ± 11.9%, N.S.). The onset and washout of PST2744 inotropic
effect were considerably faster than those of digoxin, as illustrated
in Fig. 2c for the onset of two equieffective concentrations. When
comparing equieffective concentrations, the incidence of
aftercontractions, a sign of toxicity, was significantly lower for
PST2744 than for digoxin (Fig. 2d, inset). Because inotropic potency
differed between the two agents, differences in toxicity can be best
appreciated by plotting the proportion of cells developing
aftercontractions as a function of the inotropic response that could be
achieved before their onset (Fig. 2d). This analysis shows that the
percentage of increase in twitch amplitude (i.e., the inotropic effect)
that could be achieved in the absence of aftercontractions was up to 60% for PST2744 and below 20% for digoxin.
|
Inotropy in Isolated Guinea Pig Atria. PST2744 concentration-dependently increased the force of contraction of guinea pig paced left atria in the range 0.3 to 30 µM. The maximum increase in force averaged 140 ± 16% of control (n = 4) with an EC50 value of 8.1 ± 1.25 µM. Digoxin was active in the range 0.03 to 1 µM, inducing a maximum inotropy of 180 ± 29% with an EC50 value of 0.38 ± 0.05 µM (n = 6) The digoxin/PST2744 potency ratio was 21.3 in this preparation.
In Vivo Assays
Inotropic and Toxic Effect in Anesthetized Guinea Pigs. Normal animals. The main results seen during infusion of 0.2 mg/kg/min PST2744 and 0.016 mg/kg/min digoxin are shown in Figs. 3-5. Data on PST2744 refer to the whole 90-min duration of infusion, whereas those on digoxin are restricted to the first 60 min of infusion, because thereafter the occurrence of arrhythmias prevented recording of hemodynamic parameters.
PST2744 induced a progressive increase in +dP/dtmax throughout the infusion (Fig. 3) that reached 80% (ED80) at the cumulative dose of 1.89 ± 0.37 mg/kg and a peak of 140 ± 3.5% at the dose (EDmax) of 4.88 ± 0.6 mg/kg (Table 1). A comparable increase (127 ± 26%) was afforded by digoxin at a 6-fold lower cumulative dose of 0.76 ± 0.095 mg/kg. Digoxin ED80 was 0.32 ± 0.039 mg/kg. Both compounds increased the maximum relaxation velocity (
dP/dtmax); however, the
maximum effect was substantially larger for PST2744 (72% at 3.3 mg/kg)
than for digoxin (33% at 0.56 mg/kg; p < 0.05 versus
PST2744).
|
|
|
|
Animals with cardiac failure. Total heart weight was 2742 ± 56 mg in pressure-overloaded animals compared with 2164 ± 50 mg in the respective sham group (p < 0.001). The left ventricle weight normalized to body weight increased by 28% (p < 0.01) and atrial weight by 70% (p < 0.01), showing the presence of significant left ventricle hypertrophy and atrial enlargement. Lung congestion was also observed, with lung weight-to-body weight index (milligrams per gram) increasing from 4.47 ± 0.07 to 7.94 ± 0.33 (p < 0.001). Thus, 8 weeks after constriction of the descending aorta left ventricle hypertrophy and failure could be demonstrated. These morphometric parameters were equivalent in the animals randomly assigned to treatment with 0.2 mg/kg/min PST 2744 or 0.018 mg/kg/min digoxin.
As detailed in Table 2, potency and toxicity of either compound were unaffected by the presence of HF. In total, 44% of HF animals receiving PST 2744 died at a cumulative dose 8 times higher than the ED80 (16.9 versus 2.05 mg/kg), whereas the remaining 56% survived to a maximum dose of 18 mg/kg. In contrast, digoxin caused death in 100% of the animals at a cumulative dose (1.16 ± 0.07 mg/kg) only 3 times higher than the ED80 (0.39 mg/kg).
|
Reversal of Inotropy. In some experiments (n = 6 each), infusion was discontinued to evaluate the time course of washout of inotropic effects. At the interruption of infusions producing comparable inotropic effects of the two drugs, the time required for a 50% reduction of +dP/dtmax was 6.0 ± 0.39 min for PST2744 and 18.3 ± 4.5 min for digoxin (p < 0.05).
Dose-Response in Anesthetized Dog.
Basal HR and
+dP/dtmax values were similar in PST2744
(n = 4) and digoxin (n = 3) treatment
groups [HR (bpm): 135 ± 13 versus 140 ± 7;
+dP/dtmax (mm Hg/s): 2658 ± 96 versus
3122 ± 202]. Both agents dose-dependently increased
+dP/dtmax (p < 0.001; Fig.
6) with a threshold at 32 µg/kg for
PST2744 and at 60 µg/kg for digoxin; at the latter dose digoxin
produced an effect comparable with the one of PST2744 at a similar
dose. Although HR was dose-dependently decreased by digoxin
(p < 0.05), to a minimum of 97 bpm (n = 2 for this dose), an increase to a maximum of 187 ± 4 bpm was
observed with PST2744 (p < 0.05), mostly due to the
effect of the highest dose.
|
Hemodynamic Effects in Dogs with Myocardial Infarction during
Exercise.
The resting hemodynamic parameters for the three
experimental groups obtained before and after compound administration
are shown in Table 3. Pretreatment values
did not differ. PST2744 significantly increased resting values of LVP
(p < 0.001), SBP (p < 0.05), and
+dP/dtmax (p < 0.01). Digoxin
significantly decreased HR (p < 0.05), without
modifying the other parameters.
|
|
|
|
|
| |
Discussion |
|---|
|
|
|---|
Results from these studies carried out in two species, guinea pig and dog, show that PST2744 is a potent inotropic agent both under anesthesia and in the conscious state, and signally during exercise-induced increase in workload. Importantly, under all experimental conditions PST2744 seems endowed with substantially greater safety than the reference inotropic drug digoxin. Safety in vivo is related to a lower incidence of arrhythmias and arrhythmia-sustained death. Experiments in isolated myocytes indicate that this correlates with a lower incidence of aftercontractions.
The conclusion that PST2744 possesses a significantly higher safety ratio than digoxin is supported by the following findings. In isolated guinea pig myocytes no aftercontractions were elicited by a PST2744 concentration able to increase cell shortening up to 60%, whereas with digoxin, aftercontractions ensued already at a 20% increase in cell shortening. In anesthetized guinea pigs, inotropic effects that could be obtained with PST2744 in the absence of death were achieved by a dose of digoxin causing 100% mortality. Even when PST2744 infusion rate was increased to induce death, its LD/ED80 ratio was over 6-fold larger than that of digoxin. PST2744 maintained a greater safety than digoxin also in the presence of heart failure induced by pressure overload. In anesthetized dogs digoxin induced arrhythmias and death at the threshold inotropic dose; conversely, nonlethal arrhythmias with PST2744 were first observed at a dose increasing +dP/dtmax by over 4000 mm Hg/s and 7.8 times higher than the threshold inotropic one.
Some important qualitative differences also exist between PST2744 and digoxin inotropic effects. First, the rate of onset and decay of inotropic effect was significantly faster for PST2744 both in isolated myocytes and in anesthetized guinea pigs. Second, during sustained drug exposure, although the inotropic effect of PST2744 easily reached a plateau, the one of digoxin slowly drifted until the appearance of aftercontractions (myocytes) or arrhythmias (anesthetized guinea pigs). Finally, in dogs with a myocardial infarction, exercise was associated with an increase in LVEDP, possibly reflecting latent diastolic dysfunction. Noticeably, PST2744 reversed such a pattern. This effect of PST2744 may conceivably be related to the positive lusitropic properties clearly seen in the anesthetized guinea pig.
We did not aim herein at clarifying the mechanism underlying the
greater safety of PST2744. The differences disclosed in this study
between the two
Na+/K+-ATPase inhibitors
PST27444 and digoxin might underlie differences in their mechanism of
action. We might speculate that because aftercontractions due to
digitalis glycosides have recently been shown to depend on the reversal
of the Na+-Ca2+ exchanger
transport mode (Satoh et al., 2000
; Sagawa et al., 2002
), PST2744
interaction with this transporter may differ from that of digoxin.
Characterization of PST2744 effect on the
Na+-Ca2+ exchanger needs to
be performed in view of the reported up-regulation of this transporter
in human failing hearts (Studer et al., 1994
; Flesch et al., 1996
;
Reinecke et al., 1996
) and of the reciprocal regulation between cardiac
Na+/K+-ATPase and
Na+-Ca2+ exchanger (Magyar
et al., 1995
). Although we demonstrated herein a selective interaction
of PST2744 for the
Na+/K+-ATPase receptor,
findings such as the positive lusitropy not shared by digoxin are
strongly suggestive of peculiarities in Ca2+
handling mechanisms. Likewise, it may not be excluded that PST2744 interacts with a discrete isoform of the
Na+/K+-ATPase enzyme,
because it has been suggested that different isoforms may be
responsible for the inotropic and arrhythmogenic effects (Zahler et
al., 1992
, 1996
; James et al., 1999
). In this respect, the wide
disparity in potencies toward guinea pig and canine
Na+/K+-ATPase kidney
receptor displayed by PST2744 at variance with digoxin might reflect
interaction with different isoforms, although species specificity is
probably more likely.
Further peculiarities of PST2744 in comparison with digoxin were found in whole animal experiments. In anesthetized guinea pigs, a transient decrease in HR occurred during the early infusion period with PST2744, followed by a return toward control values in spite of continuing infusion. This pattern of HR changes was paralleled by a transient increase in SBP having the same time course. In contrast, a slow and steady negative chronotropic effect was observed with digoxin. Thus, the HR reduction induced by PST 2744 in the guinea pig seems to be secondary to baroreceptor response to blood pressure increase and may thus differ from that of digoxin, commonly attributed to vagal activation. The negative chronotropic effect of digoxin was also found in both anesthetized and conscious dog. Conversely, in the former, although at the highest doses, the effect of PST2744 on HR was opposite to that of digoxin. Thus, it may be concluded that, unlike digoxin, PST2744 does not stimulate the vagal tone.
The experimental exercise model used herein deserves comment because it
mimics a functionally relevant condition in humans, i.e., the increase
in workload induced by physical activity in a condition of mild
ischemia. Importantly, PST2744-treated dogs show a favorable
hemodynamic profile at a stage of submaximal well tolerated stress
(Table 4). This infarction model does not easily evolve into heart
failure. The healed infarcted myocardium has, however, been reported as
a site of enhanced susceptibility to glycosides toxicity (Iesaka et
al., 1983
). Importantly, when an acute ischemic episode was added to
the background ischemia by occluding the circumflex artery, PST2744 did
not exhibit proarrhythmogenic properties. To this regard it should be
mentioned that the doses used in this experiment for either compounds
were 20 to 25% above those found to be arrhythmogenic in the
anesthetized dog, because preliminary experiments showed that
anesthesia increases the susceptibility to arrhythmias.
Whether the peculiar features of PST2744 described above reflect different pharmacokinetic properties, interaction with specific Na+/K+-ATPase isoforms, or a different regulation of the Na+-Ca2+ exchanger is not known. We demonstrated a selective interaction of PST2744 with the Na+/K+-ATPase receptor, excluding all known inotropic mechanisms; however, interaction with yet unknown mechanisms or different postreceptor mechanisms may not be ruled out.
In conclusion, a low propensity of PST2744 to induce rhythm disturbance was seen in all experimental settings used, and differentiates the compound from digoxin, the most commonly prescribed cardiac glycoside used as reference drug. Results in isolated myocytes suggest that the underlying cause for this difference resides mainly at the cell level. Finally, if the faster rate of onset and dissipation of effects seen with PST2744 could be extrapolated to the clinical setting, PST2744 might be anticipated to have better therapeutic handling and a larger safety margin against fluctuation of drug plasma levels than digoxin.
| |
Footnotes |
|---|
Accepted for publication July 3, 2002.
Received for publication May 9, 2002.
DOI: 10.1124/jpet.102.038331
Address correspondence to: Rosella Micheletti, Prassis Sigma-Tau Research Institute, Via Forlanini 1/3, 20019 Settimo Milanese, Italy. E-mail: rosella.micheletti{at}prassis.it
| |
Abbreviations |
|---|
HF, heart failure;
LVP, left ventricular
pressure;
+dP/dtmax, maximum velocity of pressure rise;
HR, heart rate;
dP/dtmax, maximum velocity of pressure fall;
ED80, dose increasing +dP/dtmax by 80%;
EDmax, dose inducing the maximum increase in
+dP/dtmax;
LD, lethal dose;
DMSO, dimethyl sulfoxide;
bpm, beats per minute;
LVEDP, left ventricular end diastolic pressure;
SBP, systolic blood pressure.
| |
References |
|---|
|
|
|---|
-substituted seco-D-5
-androstane as cassaine analogs.
J Med Chem
41:
3033-3040[CrossRef][Medline].
-O-(Aminoalkyl)oxime derivatives of 3
,14
-dihydroxy-5
-androstane and 3
-hydroxy-14-oxoseco-D-5
-androstane as inhibitors of Na+,K+-ATPase at the digitalis receptor.
J Med Chem
44:
3821-3830[CrossRef][Medline].
2 isoform as regulator of calcium in the heart.
Mol Cell
3:
555-563[CrossRef][Medline].
2 and
3 isoforms of the Na+,K+-ATPase.
Proc Natl Acad Sci USA
89:
99-103
3 isoform protein of the Na+, K+-ATPase is associated with the sites of cardiac and neuromuscular impulse transmission.
Circ Res
78:
870-879This article has been cited by other articles:
![]() |
G. G. Mattera, E. Vanoli, J.-P. Gagnol, F. M. P. Loi, F. Borsini, and P. Carminati Sympathomimetic inefficiency in restoring contractility in the acute or chronic {beta}-blocker-treated ischaemic heart: Comparison with a new agent Eur J Heart Fail, October 1, 2008; 10(10): 990 - 996. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rocchetti, M. Alemanni, G. Mostacciuolo, P. Barassi, C. Altomare, R. Chisci, R. Micheletti, P. Ferrari, and A. Zaza Modulation of Sarcoplasmic Reticulum Function by PST2744 [Istaroxime; (E,Z)-3-((2-Aminoethoxy)imino) Androstane-6,17-dione Hydrochloride)] in a Pressure-Overload Heart Failure Model J. Pharmacol. Exp. Ther., September 1, 2008; 326(3): 957 - 965. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gheorghiade, J. E.A. Blair, G. S. Filippatos, C. Macarie, W. Ruzyllo, J. Korewicki, S. I. Bubenek-Turconi, M. Ceracchi, M. Bianchetti, P. Carminati, et al. Hemodynamic, Echocardiographic, and Neurohormonal Effects of Istaroxime, a Novel Intravenous Inotropic and Lusitropic Agent: A Randomized Controlled Trial in Patients Hospitalized With Heart Failure J. Am. Coll. Cardiol., June 10, 2008; 51(23): 2276 - 2285. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. De Luca, A. Mebazaa, G. Filippatos, J. T. Parissis, M. Bohm, A. A. Voors, M. Nieminen, F. Zannad, A. Rhodes, A. El-Banayosy, et al. Overview of emerging pharmacologic agents for acute heart failure syndromes Eur J Heart Fail, February 1, 2008; 10(2): 201 - 213. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Schoner and G. Scheiner-Bobis Endogenous and exogenous cardiac glycosides: their roles in hypertension, salt metabolism, and cell growth Am J Physiol Cell Physiol, August 1, 2007; 293(2): C509 - C536. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. M. deGoma, R. H. Vagelos, M. B. Fowler, and E. A. Ashley Emerging Therapies for the Management of Decompensated Heart Failure: From Bench to Bedside J. Am. Coll. Cardiol., December 19, 2006; 48(12): 2397 - 2409. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rocchetti, A. Besana, G. Mostacciuolo, R. Micheletti, P. Ferrari, S. Sarkozi, C. Szegedi, I. Jona, and A. Zaza Modulation of Sarcoplasmic Reticulum Function by Na+/K+ Pump Inhibitors with Different Toxicity: Digoxin and PST2744 [(E,Z)-3-((2-Aminoethoxy)imino)androstane-6,17-dione Hydrochloride] J. Pharmacol. Exp. Ther., April 1, 2005; 313(1): 207 - 215. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Rocchetti, A. Besana, G. Mostacciuolo, P. Ferrari, R. Micheletti, and A. Zaza Diverse Toxicity Associated with Cardiac Na+/K+ Pump Inhibition: Evaluation of Electrophysiological Mechanisms J. Pharmacol. Exp. Ther., May 1, 2003; 305(2): 765 - 771. [Abstract] [Full Text] [PDF] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||